All type of patients: 4 trials - RESILIENCE - Schwartzberg - Gradishar - Baselga
| sorafenib + capecitabine vs capecitabine alone | No demonstrated result suggested progression or death (progression free survival PFS) by 42% (not demonstrated) | |
| sorafenib + gemcitabine or capecitabine vs gemcitabine or capecitabine alone | No demonstrated result suggested progression or death (progression free survival PFS) by 36% (not demonstrated) | |
| sorafenib + paclitaxel vs paclitaxel alone | No demonstrated result |
All type of patients: 4 trials - Wakelee - Paz-Ares - Spigel - Scagliotti
| sorafenib vs | No demonstrated result | |
| sorafenib vs placebo | No demonstrated result | |
| sorafenib and erlotinib vs erlotinib | No demonstrated result |
All type of patients: 3 trials - Escudier - TARGET - Ratain
| sorafenib vs interferon alpha | No demonstrated result | |
| sorafenib vs placebo | No demonstrated result suggested progression or death (progression free survival PFS) by 56% (not demonstrated) |
-
About
-
Browse pathology
|
treatment
-
Site map
-
Credits
Made with in Lyon
-
Contact us
-
Privacy policy
-
